MS Views and News Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter

MS Views and News uses state-of-the-art technology to provide resources to the MS Community. Visit our MS learning channel on YouTube, to gain knowledge from hundreds of MS educational videos presented by MS Experts from across the USA. Click:

Within this blog you can find MS resources by viewing all showing below pertaining to thousands of MS articles, resources, event timing. Additionally, please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for those affected by Multiple Sclerosis. * From the comfort of your home, you can join us for our VIRTUAL MS events. To learn more of these virtual events please subscribe here.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, March 31, 2018

Why Clinical Trials Matter - You play an essential role

Before a potential new medicine can be used to help treat patients, it must go through a series of studies in people. Volunteers like you who take part in clinical trials make valuable contributions to advancing the understanding of diseases and the discovery of new or improved treatments.

How your participation helps

Each year, millions of people help advance medical science by volunteering to take part in clinical trials. While there are many reasons for participating, all who volunteer contribute valuable information to help researchers find better treatments that may improve lives.
Information republished

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides beneficial Multiple Sclerosis education, information, resources and services. 

Thursday, March 29, 2018

• GeNeuro-Servier Antibody Limits RRMS Patients’ Brain Shrinkage, Phase 2b Trial Shows

March 29, 2018

The laboratory-generated antibody GNbAC1 continued to limit brain shrinkage a year after relapsing-remitting multiple sclerosis patients began receiving it, its developers announced.
GeNeuro and Servier were reporting on the 12-month results of a Phase 2b clinical trial.
GNbAC1 is a monoclonal antibody that destroys a harmful retroviral protein called pHERV-W which scientists have linked to brain lesions in MS patients. Lesions are areas where the myelin coating that protects nerve cells has deteriorated.
The Phase 2b CHANGE-MS trial (NCT02782858), conducted in 12 European countries, involved 270 RRMS patients. Researchers randomized them to receive the antibody or a placebo once a month by intravenous infusion.
GeNeuro and Servier said a year’s worth of GNbAC1 led to much brain loss among MS patients than a regimen consisting of six months of a placebo and six months of the antibody. The difference in brain atrophy was 31 percent in the brain’s cortical area and 72 percent in the thalamic areas.
Read more

SUBSCRIBE to our MS Learning Channel on YouTube:

Sunday, March 25, 2018

Predicting Episodic Memory Loss in Patients with MS

Mult Scler; ePub 2018 Mar 7; Koenig, et al
March 20, 2018

Functional activation may be useful as a predictive measure of episodic memory loss in patients with multiple sclerosis (MS), a recent study found. Researchers used functional magnetic resonance imaging (fMRI) during a verbal episodic memory task, lesion load, and volumetric measures of the hippocampus and thalamus to assess the relative contributions to verbal and visual-spatial episodic memory in persons with MS (n=32) and healthy controls (n=16). They found:

  • After adjusting for disease duration, immediate recall performance on a visual-spatial episodic memory task was significantly predicted by hippocampal volume.
  • Delayed recall on the same task was significantly predicted by volume of the left thalamus.
  • For both memory measures, functional activation of the thalamus during encoding was more predictive than that of volume measures.

Read more

MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis
MS Views and News provides Multiple Sclerosis education, information, resources and services that will benefit many affected by MS. 
SUBSCRIBE to our MS Learning Channel on YouTube:

Sun Exposure Associated with Lower MS Risk

Neurology; ePub 2018 Mar 7; Tremlett, et al
March 20, 2018

Living in high ambient UV-B areas during childhood and the years leading up to multiple sclerosis (MS) onset was associated with a lower MS risk, according to a recent study. Furthermore, high summer sun exposure in high ambient UV-B areas was also associated with a reduced risk. Persons with MS (n=151) and age-matched controls (n=235) from the Nurses' Health Study cohorts completed questionnaires that assessed summer, winter, and lifetime sun exposure history. Relative risks and 95% confidence intervals were estimated via conditional logistic regression with adjustment for body mass index, ancestry, smoking, and vitamin D supplementation. They found:

  • Most participants were white (98%); the mean age at MS onset was 39.5 years.
  • Living in high (vs low) UV-B areas before MS onset was associated with a 45% lower MS risk.
  • Similar reduced risks (51%–52%) for medium or high exposure were observed at ages 5 to 15 years and at 5 to 15 years before MS onset.
  • At age 5 to 15 years, living in a high (vs low) UV-B area and having high (vs low) summer sun exposure were associated with a lower MS risk.



SUBSCRIBE to our MS Learning Channel on YouTube: